IP Library Granted Patent US 12692440
Granted Patent B2
US 12692440 · App. 18/867,267 · Granted Jul 28, 2026

Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element

Inventors: Yuta Iizuka (Funabashi, JP); Masato Moriuchi (Funabashi, JP)
Assignee: NISSAN CHEMICAL CORPORATION
C09K19/3003C09K19/066C09K19/3411C09K2019/3004C09K2019/3009C09K2019/3408C09K2019/3425
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692440
App. No.
18/867,267
Granted
Jul 28, 2026
Kind
B2
Abstract

The present invention provides: a liquid crystal alignment film which has good liquid crystal alignment properties, while having excellent pretilt angle developability; a liquid crystal display element which is provided with this liquid crystal alignment film; and a liquid crystal aligning agent which enables the achievement of this liquid crystal alignment film. The present invention provides a liquid crystal aligning agent which contains: as a component (A), a compound that has a thermally crosslinkable group and a photo-alignment group represented by formula (pa-1), wherein the thermally crosslinkable group is capable of forming a covalent bond by being reacted with a carboxy group; and as a component (B), a polyamic acid and a solvent. (In formula (pa-1), A represents a phenylene group or the like; R1 represents —COO— or —OCO—; R2 represents a cyclohexane-1,4-diyl group; R3 represents a cyclohexane-1,4-diyl group; R4 represents a linear or branched alkyl group having 1 to 40 carbon atoms, and some or all of the hydrogen atoms in this alkyl group may be substituted by fluorine atoms; D represents an oxygen atom, a sulfur atom or —NRd-; a represents an integer of 0 to 3; and * denotes a bonding position.)

Claims (2)

1 . A compound represented by any one of the following formulas (paa-1-ma1) to (paa-1-ma4):

wherein (E) in the formulas (paa-1-ma1), (paa-1-ma2), (paa-1-ma3) and (paa-1-ma4) each represents the E form, and t in the formulas (paa-1-ma1), (paa-1-ma2), (paa-1-ma3) and (paa-1-ma4) each represents the trans form of the cyclohexyl group.